ABRAXANE accepted for restricted use within Scotland NHS

[News]

Abraxis BioScience, Inc., a fully integrated biotechnology company, welcomes the announcement today that following a full submission, the Scottish Medicines Consortium (SMC) has accepted ABRAXANE® (paclitaxel albumin) for restricted use within the National Health Service (NHS) for Scotland in patients who would otherwise receive docetaxel or 3-weekly solvent-based paclitaxel as second-line treatment for metastatic breast cancer.

More... (http://www.news-medical.net/news/20100413/ABRAXANE-accepted-for-restricted-use-within-Scotland-NHS.aspx)